1. DEFINITION AND ETIOLOGY

  • Definition: An autosomal recessive disorder of tyrosine metabolism characterized by the accumulation of homogentisic acid (HGA) due to an enzyme deficiency.
  • Enzyme Defect: Deficiency of Homogentisate 1,2-dioxygenase (HGD).
  • Gene: HGD gene located on chromosome 3q13.
  • Inheritance: Autosomal Recessive.
  • Epidemiology: Rare (1:250,000); higher prevalence in Slovakia and Dominican Republic.

2. PATHOPHYSIOLOGY

  • Metabolic Block: Failure to convert Homogentisic Acid (HGA) to Maleylacetoacetic Acid in the tyrosine catabolic pathway.
  • Mechanism of Damage:
    1. HGA Accumulation: HGA levels rise markedly in blood and urine.
    2. Oxidation: HGA oxidizes to benzoquinone acetic acid, which polymerizes to form a dark pigment (Alkapton).
    3. Deposition (Ochronosis): This pigment has a high affinity for connective tissue (cartilage, skin, sclera), leading to tissue weakness and degeneration.
  • Urine Change: HGA in urine oxidizes upon exposure to air or alkalization, turning the urine dark brown or black.

3. CLINICAL FEATURES

The disease evolves in three stages:

A. Infancy and Childhood (Asymptomatic Stage)

  • Dark Urine: The only early symptom.
    • Urine turns black upon standing for hours or if alkalinized (e.g., washing diapers with soap).
    • Often unrecognized ("staining of diapers") or misdiagnosed.
  • General: Asymptomatic otherwise; normal growth and development.

B. Young Adulthood (Ochronosis Stage)

  • Ochronosis: Blue-black pigmentation of connective tissues (usually appears in 3rd–4th decade).
    • Ears: Slate-blue discoloration of ear cartilage; earwax is black.
    • Eyes: Brown/black pigment spots on the sclera (Osler's sign) midway between cornea and canthus.
    • Skin: Axillary and inguinal pigmentation.

C. Adulthood (Arthropathy Stage)

  • Ochronotic Arthropathy:
    • Degenerative arthritis resembling osteoarthritis but occurring at a younger age.
    • Spine: Affects large joints and spine first. Loss of lumbar lordosis, ankylosis, and severe back pain.
    • Knees/Hips/Shoulders: Severe secondary osteoarthritis often requiring joint replacement.
  • Cardiovascular: Calcification and stenosis of the aortic or mitral valves; risk of coronary artery calcification.
  • Genitourinary: Black prostatic calculi.

4. INVESTIGATIONS

  • Urine Tests:
    • Visual: Urine turns black on standing or adding alkali (NaOH).
    • Reducing Substances: Positive Benedict’s test (HGA is a reducing agent) but Negative Clinistix (Glucose oxidase).
    • Ferric Chloride Test: Transient purple-black color.
  • Confirmatory:
    • Gas Chromatography-Mass Spectrometry (GC-MS): Detects massive elevation of Homogentisic Acid (HGA) in urine.
  • Radiology:
    • Spine X-ray: Calcification of intervertebral discs (pathognomonic sign). Narrowing of disc spaces and vertebral fusion (Bamboo spine appearance similar to Ankylosing Spondylitis).
  • Genetics: Molecular analysis of HGD gene.

5. DIFFERENTIAL DIAGNOSIS (DARK URINE)

  • Porphyria (turns dark on standing).
  • Hemoglobinuria/Myoglobinuria.
  • Drugs (Methyldopa, Metronidazole).
  • Melaninuria (Melanoma).

6. MANAGEMENT

Goal: Reduce HGA production and manage complications.

A. Specific Therapy

  • Nitisinone (NTBC):
    • Mechanism: Inhibits the enzyme 4-hydroxyphenylpyruvate dioxygenase (upstream of the defect).
    • Effect: Prevents the formation of HGA.
    • Clinical Use: Shown to reduce HGA levels by 95% and slow the progression of ochronosis and cardiac pathology.
    • Side Effect: Causes Hypertyrosinemia (requires dietary tyrosine/phenylalanine restriction to prevent corneal crystals).

B. Symptomatic Treatment

  • Diet: Restriction of protein (phenylalanine and tyrosine) helps reduce HGA load (difficult to maintain long-term).
  • Vitamin C (Ascorbic Acid): High dose; prevents oxidation of HGA to pigment but does not reduce HGA levels. Clinical efficacy is doubtful.
  • Orthopedic: Physiotherapy, analgesia, and joint replacement surgery (hip/knee) for severe arthritis.
  • Cardiac: Valve replacement for severe aortic stenosis.

7. PROGNOSIS

  • Life expectancy is generally normal.
  • Morbidity is high due to severe, crippling arthritis and cardiovascular disease in later life.